Two phase 3 trials of lebrikizumab for moderate-to-severe atopic dermatitis
Background Lebrikizumab, a high-affinity IgG4 monoclonal antibody targeting interleukin-13,
prevents the formation of the interleukin-4Rα–interleukin-13Rα1 heterodimer receptor …
prevents the formation of the interleukin-4Rα–interleukin-13Rα1 heterodimer receptor …
Dupilumab in children aged 6 months to younger than 6 years with uncontrolled atopic dermatitis: a randomised, double-blind, placebo-controlled, phase 3 trial
Background Current systemic treatments for children younger than 6 years with moderate-to-
severe atopic dermatitis that is uncontrolled with topical therapies might have suboptimal …
severe atopic dermatitis that is uncontrolled with topical therapies might have suboptimal …
Efficacy and safety of lebrikizumab in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis: a randomized …
EL Simpson, M Gooderham, A Wollenberg… - JAMA …, 2023 - jamanetwork.com
Importance Lebrikizumab (LEB), a high-affinity monoclonal antibody targeting interleukin (IL)-
13, demonstrated efficacy and safety in patients with moderate-to-severe atopic dermatitis …
13, demonstrated efficacy and safety in patients with moderate-to-severe atopic dermatitis …
Biologics for allergy: therapeutic potential for ocular allergic diseases and adverse effects on the eye
K Fukuda, T Kishimoto, T Sumi, K Yamashiro… - Allergology …, 2023 - jstage.jst.go.jp
abstract Biologics applying antibodies against IgE, IL-5, IL-5 receptor a, IL-4 receptor a, and
IL-13 have dramatically improved recent treatment outcomes in allergic diseases including …
IL-13 have dramatically improved recent treatment outcomes in allergic diseases including …
Anti-inflammatory and biologic drugs for atopic dermatitis: a therapeutic approach in children and adolescents
C Caffarelli, A Giannetti, G Giannì, G Ricci - Frontiers in Medicine, 2023 - frontiersin.org
Atopic dermatitis (AD) is a chronic inflammatory disease with a heterogeneous pathogenesis
correlated with dysregulation of the immune system and a prevalence of the T2-mediated …
correlated with dysregulation of the immune system and a prevalence of the T2-mediated …
Efficacy and safety of tralokinumab in adolescents with moderate to severe atopic dermatitis: the phase 3 ECZTRA 6 randomized clinical trial
Importance Safe and effective long-term treatments for adolescents with moderate to severe
atopic dermatitis (AD) are limited. Objective To evaluate the efficacy and safety of interleukin …
atopic dermatitis (AD) are limited. Objective To evaluate the efficacy and safety of interleukin …
Safety of tralokinumab in adult patients with moderate‐to‐severe atopic dermatitis: pooled analysis of five randomized, double‐blind, placebo‐controlled phase II and …
Background Tralokinumab is a fully human monoclonal antibody that neutralizes the activity
of interleukin‐13, a key pathogenic driver of atopic dermatitis (AD). Clinical trials including …
of interleukin‐13, a key pathogenic driver of atopic dermatitis (AD). Clinical trials including …
Safety of lebrikizumab in adults and adolescents with moderate-to-severe atopic dermatitis: an integrated analysis of eight clinical trials
Background Lebrikizumab is a monoclonal antibody that binds with high affinity to
interleukin (IL)-13, thereby blocking the downstream effects of IL-13 with high potency …
interleukin (IL)-13, thereby blocking the downstream effects of IL-13 with high potency …
Switching from dupilumab to tralokinumab in atopic dermatitis patients with ocular surface disease: preliminary case series
R Achten, C Dekkers, D Bakker… - Clinical & …, 2023 - Wiley Online Library
To the Editor, Since 2018, new biological therapies that target pathways involved in the
pathogenesis of atopic dermatitis (AD) are available to treat patients with moderate-to …
pathogenesis of atopic dermatitis (AD) are available to treat patients with moderate-to …
Dupilumab‐associated ocular surface disease in atopic dermatitis patients: Clinical characteristics, ophthalmic treatment response and conjunctival goblet cell …
R Achten, J Thijs, M van Der Wal, C van Luijk… - Allergy, 2023 - Wiley Online Library
Background Dupilumab‐associated ocular surface disease (DAOSD) is frequently reported
as side effect in atopic dermatitis (AD) patients. Therefore, the aim of this study was to …
as side effect in atopic dermatitis (AD) patients. Therefore, the aim of this study was to …